Liposomal Composition for Agricultural and Veterinary Applications
Legal Citation
Summary of the Inventive Concept
This inventive concept leverages the core technology of docetaxel liposomes to target pest cells, fungal infections, parasitic infections, and aquaculture diseases in agricultural and veterinary fields, offering a novel solution for these industries.
Background and Problem Solved
The original patent focused on developing docetaxel liposomes for cancer treatment, but its limitations in terms of targeting and delivery can be overcome by applying this technology to other industries. The new inventive concept addresses the need for effective solutions in agricultural pest control, veterinary medicine, and aquaculture.
Detailed Description of the Inventive Concept
The liposomal composition consists of docetaxel, Soya Phosphatidyl Choline, Sodium Cholesteryl Sulfate, and Sucrose, with specific weight percentages and pH adjustments. This composition is designed to target pest cells, fungal infections, parasitic infections, and aquaculture diseases, providing a targeted and efficient delivery system.
Novelty and Inventive Step
The new claims introduce a novel application of docetaxel liposomes in agricultural and veterinary fields, which is non-obvious compared to the original patent's focus on cancer treatment. The inventive step lies in adapting the liposomal composition to target specific cells and diseases in these industries.
Alternative Embodiments and Variations
Other embodiments of the inventive concept could include varying the weight percentages of the liposomal composition, adjusting the pH, or incorporating additional components to enhance targeting and delivery. These variations could be explored to further expand the scope of the inventive concept.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the agricultural and veterinary industries, offering a novel solution for pest control, fungal infections, parasitic infections, and aquaculture diseases. The target market includes companies involved in agricultural pest control, veterinary medicine, and aquaculture, as well as research institutions exploring new applications for liposomal technology.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K9/127 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K9/1277 |
| A | A61 | A61K31/337 |
| A | A61 | A61K47/24 |
| A | A61 | A61K47/26 |
| A | A61 | A61K47/28 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical formulation and drug delivery systems, specifically liposomal compositions for targeted drug delivery across medical and agricultural applications, with expertise in lipid-based drug encapsulation techniques and formulation optimization
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical scientist or formulation engineer with advanced degrees in chemistry or pharmaceutical sciences, experienced in liposomal drug delivery, familiar with drug encapsulation techniques, solvent interactions, and cross-industry drug application strategies
Obviousness Rationale
A PHOSITA would recognize that the core liposomal composition from the source patent (US 11857680) represents a versatile drug delivery platform that can be readily adapted to different target applications by modifying the intended use while maintaining substantially identical formulation parameters. The technical variations proposed in the PTD represent predictable extensions of the original liposomal technology, utilizing known lipid encapsulation principles to target alternative cellular environments beyond oncological treatments.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,680 |
|---|---|
| Title | Composition of docetaxel liposomal injection with high drug loading |
| Assignee(s) | SHILPA MEDICARE LIMITED |